1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Co., Ltd.

LSBPW
LakeShore Biopharma Co., Ltd.US flagNASDAQ Global Market
0.01
USD
- -
- -
307,879.00Market Cap
LakeShore Biopharma Co., Ltd.
LSBPW
(NASDAQ Global Market)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
257
503
687
573
615
Sales/Revenue/Turnover
-47.59
-17.19
-15.23
-46.69
-7.23
Operating Margin (%)
28
31
37
42
37
Depreciation Expense
-192
-106
-145
-433
-100
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-74.64
-21.08
-21.17
-75.59
-16.26
Profit Margin (%)
388
289
377
101
17
Working Capital
15
265
300
101
24
LT Debt
-509
-699
728
585
500
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-14.6%
Free Cash Flow
- -
- -
-59.1%
Net Income, GAAP
- -
- -
-76.93%
Sales/Revenue/Turnover
- -
- -
7.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
205
194
- -
- -
687
2024
176
97
- -
- -
573
2025
- -
- -
- -
- -
615

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
LakeShore Biopharma Co., Ltd (LSBCF)
OmniAb, Inc. Common Stock When Issued (OABIV)
MEDIPOST Co., Ltd. (078160.KQ)
HOOKIPA Pharma Inc. (HOOK)
Bioneer Corp (064550.KS)
Regeneus Ltd (RGS.AX)
Business
LakeShore Biopharma Co., Ltd. is a global biopharmaceutical entity focused on the discovery, development, production, and commercialization of cutting-edge vaccines and therapeutic biologics for battling infectious diseases and various cancers. The company leverages its proprietary PIKA immunomodulating technology platform, which activates immune signaling pathways, to advance a diverse pipeline of products. This includes an innovative PIKA rabies vaccine currently undergoing a Biologics License Application submission in Pakistan and holding Orphan Drug Designation from the U.S. FDA, along with a PIKA recombinant COVID-19 vaccine and PIKA YS-ON-001, an immunotherapy for cancer that completed its Phase I trial in 2023. The company also offers its established YSJA™ rabies vaccine, a market leader in China, which recently saw the launch of a novel, safer packaging solution in April 2025, and is progressing with a Phase III trial for a simplified dosing regimen. Operating across China, the United States, Singapore, the United Arab Emirates, and the Philippines, LakeShore Biopharma was originally established in 1994. The company underwent a legal name change from YS Biopharma Co., Ltd. to LakeShore Biopharma Co., Ltd. in May 2024 to better reflect its international brand and market reach. In recent developments, LakeShore Biopharma has transitioned its trading to the OTC Pink Open Market in September 2025, following a delisting from Nasdaq due to non-compliance with listing rules, and is also evaluating a preliminary non-binding proposal to be acquired.